乙型肝炎后肝硬化患者抗病毒治疗疗效及生存质量评价

The efficacy and quality of life assessment of antiviral treatment in patients with liver cirrhosis after hepatitis B

目的研究拉米夫定(LAM)联合恩替卡韦(ETV)治疗乙型肝炎后肝硬化的临床效果及对患者生存质量的影响。方法选取乙型肝炎后肝硬化患者68例,均给予LAM(100 mg/d)联合ETV(0.5 mg/d)抗病毒治疗,疗程为4个月,观察记录治疗前后相关肝功能指标、Child-Pugh评分及健康生存质量量表(SF-36)评分,以判断抗病毒治疗对乙型肝炎后肝硬化的疗效。结果经4个月治疗后,患者肝功能指标、Child-Pugh评分均较治疗前降低(P<0.01);SF-36评分升高(P<0.01)。结论对乙型肝炎后肝硬化患者行抗病毒治疗,可有效改善患者肝功能,降低Child-Pugh评分,提高生存质量。

Objective To study the efficacy and quality of life assessment of lamivudine （LAM） combined with entecavir （ ETV） in the treatment of patients with liver cirrhosis after hepatitis B .Methods Sixty-eight patients with viral cirrhosis were given a dose of LAM（100 mg/d）and ETV（0.5 mg/d）,the course was 4 months.Before and after the treatment ,the patients were tested for the liver function,Child-Pugh score and health and quality of life （SF-36） score.By comparing the differences before and after treatment , the efficacy of antiviral treatment of liver cirrhosis after hepatitis B and quality of life were evaluated .Results After a course of four months,the liver function and Child-Pugh score of all the patients were improved （ P 〈0.01）,and SF-36 score was higher than before （ P 〈0.01）.Conclusion Antiviral therapy can effectively improve hepatic function ,lower Child-Pugh score and improve the quality of life of patients with liver cirrhosis after hepatitis B .